IN8BIO, INC.

Listed Company

INABCIK 0001740279NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-19.44M

Total Assets

$32.28M

Equity

$27.56M

Shares Out

9.85M

Op. Cash Flow

$-12.71M

INAB$1.33−39.55% · past yearDBEQ Basic

Daily closing prices

Business

IN8BIO is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases. The company's DeltEx platform encompasses allogeneic, autologous, iPSC-derived, and genetically modified gamma-delta T cell product candidates designed to recognize and kill diseased cells. Key programs include INB-100 (allogeneic gamma-delta T cells for hematologic malignancies in stem cell transplant), INB-200 and INB-400 (chemotherapy-resistant autologous gamma-delta T cells for glioblastoma), and INB-600/INB-619 (gamma-delta T cell engagers for oncology and autoimmune disease). The company operates primarily through investigator-sponsored and company-sponsored clinical trials in the United States.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	10	17	17	14	7
General and administrative	10	13	14	14	7
Severance and related charges	0	1	0	—	—
Total operating expenses	20	31	30	29	15
Interest income	421,000	230,000	0	—	—
Loss from operations	−19	−30	−30	−29	−15
Net loss	−19	−30	−30	−29	−15
Net loss per share - basic	−4.44	−17.05	−1	−1.36	−1.47
Net loss per share - diluted	−4.44	−17.05	−1	−1.36	−1.47
Weighted-average number of shares used in computing net loss per common share - basic	4	2	30	21	10
Weighted average number of shares used in computing net loss per share - diluted	4	2	30	21	10

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	27	11	21	18	37
Prepaid expenses and other current assets	788,000	1	3	4	2
Total Current Assets	28	13	25	22	39
Property and equipment, net	2	3	4	4	97,000
Restricted cash	220,000	266,000	256,000	252,000	251,000
Right-of-use assets - finance leases	296,000	1	1	2	704,000
Right-of-use assets - operating leases	2	4	4	4	2
Other non-current assets	146,000	275,000	255,000	255,000	158,000
Total Non-Current Assets	4	8	9	11	3
Total Assets	32	21	34	33	42
Accounts payable	309,000	389,000	924,000	2	395,000
Accrued expenses and other current liabilities	2	1	3	2	1
Short-term finance lease liability	295,000	694,000	694,000	682,000	392,000
Short-term operating lease liability	924,000	953,000	820,000	707,000	234,000
Total Current Liabilities	3	3	5	6	2
Long-term finance lease liability	0	295,000	525,000	811,000	269,000
Long-term operating lease liability	2	3	3	4	2
Total Non-Current Liabilities	2	3	3	4	2
Total Liabilities	5	6	9	10	4
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024. No shares issued and outstanding	0	0	0	0	0
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at December 31, 2025 and 2024; 9,766,132 and 2,416,066 shares issued and outstanding at December 31, 2025 and 2024, respectively	10,000	7,000	4,000	3,000	2,000
Additional paid-in capital	169	136	116	84	71
Accumulated deficit	−141	−122	−91	−61	−33
Total Stockholders' Equity	28	14	25	23	−38
Total Liabilities and Stockholders' Equity	32	21	34	33	42

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−19	−30	−30	−29	−15
Depreciation and amortization	1	1	1	100,000	100,000
Non-cash stock-based compensation	3	5	4	3	2
Amortization of finance lease right-of-use assets	771,000	859,000	871,000	461,000	537,000
Amortization of operating lease right-of-use assets	730,000	820,000	668,000	495,000	162,000
Loss on disposal of construction in progress	0	45,000	0	—	—
Prepaid expenses and other current assets	670,000	2	689,000	−2	−2
Other non-current assets	129,000	−20,000	0	−97,000	−159,000
Accounts payable	−80,000	−535,000	−981,000	2	−319,000
Accrued expenses and other current liabilities	586,000	−2	796,000	924,000	554,000
Short-term operating lease liabilities	612,000	134,000	112,000	112,000	158,000
Long-term operating lease liabilities	−879,000	−972,000	−820,000	−526,000	−197,000
Net cash used in operating activities	−13	−24	−23	−24	−14
Purchases of property and equipment	0	−104,000	−405,000	−4	0
Construction in progress	0	−83,000	−195,000	−16,000	−309,000
Net cash used in investing activities	0	−187,000	−600,000	−4	−309,000
Proceeds from the issuance of common stock, net of issuance costs	9	4	14	10	36
Principal payments on finance leases	−693,000	−794,000	−798,000	−615,000	−535,000
Net cash provided by financing activities	29	14	27	9	33
Net increase (decrease) in cash and restricted cash	16	−10	3	−19	19
Initial measurement of operating lease right-of-use assets and liabilities	0	714,000	0	3	2
Initial measurement of finance lease right-of-use assets and liabilities	0	564,000	536,000	1	0
Lease modification of operating lease right-of-use assets and liabilities	−1	492,000	0	—	—
Lease modification of finance lease right-of-use assets and liabilities	−1,000	0	7,000	0	—
Transfer of construction in progress to property and equipment	0	221,000	29,000	403,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is IN8BIO, INC.'s CIK number?

IN8BIO, INC.'s SEC CIK number is 0001740279 (1740279). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find IN8BIO, INC.'s SEC filings?

All of IN8BIO, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did IN8BIO, INC. last report earnings?

IN8BIO, INC. (INAB) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-212128). This is IN8BIO, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is IN8BIO, INC.'s most recent earnings 8-K?

IN8BIO, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-212128. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View IN8BIO, INC.'s latest earnings 8-K →
Look up any company's CIK number →